GT Medical Technologies Secures $100M to Revolutionize Brain Tumor Treatment
June 16, 2026, 10:14 pm
Location: United States
Employees: 11-50
Founded date: 2017
Total raised: $299.4M
GT Medical Technologies secured $100 million in oversubscribed Series E funding. Viking Global Investors led the round. These funds will fuel aggressive commercial expansion and advance critical clinical trials. The company's innovative GammaTile device offers a bioresorbable implant for brain tumor patients. It provides immediate, targeted radiation at the tumor site. Recent clinical data from the ROADS trial demonstrated significant improvements in recurrence-free and overall survival rates. This pivotal investment accelerates a new standard of care. It transforms neuro-oncology treatment options for countless patients. The technology targets operable brain tumors. It minimizes collateral damage. This significant investment promises broader access and substantially improved patient outcomes.
GT Medical Technologies received $100 million. It was an oversubscribed Series E funding round. This significant capital infusion will propel the company forward. Viking Global Investors led the financing. Existing investors also participated. These included MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, and FemHealth Ventures. The investment underscores strong confidence in GT Medical Technologies' vision. It validates their innovative approach to neuro-oncology.
The proceeds will accelerate key initiatives. Commercial expansion stands as a priority. Operational capabilities will see substantial upgrades. The company plans continued investment in clinical trials. The BRIDGES randomized controlled trial is crucial. It focuses on newly diagnosed glioblastoma patients. This funding ensures robust support for future growth. It provides flexibility for strategic investments. The goal is to redefine brain tumor treatment.
At the heart of GT Medical Technologies’ mission is GammaTile. This medical device represents a paradigm shift. It is an FDA-cleared bioresorbable radiotherapy implant. GammaTile targets operable brain tumors. Its design is ingenious. It consists of small collagen tiles. Radioactive seeds (Cesium-131) are embedded within. Surgeons implant GammaTile directly during tumor removal surgery. This happens at the time of resection. The innovative approach delivers immediate treatment.
Traditional radiation therapy often involves delays. Patients typically wait weeks after surgery. GammaTile eliminates this waiting period. It provides targeted radiation immediately. The tiles deliver a precise, focused dose. This targets the highest-risk area. Remaining cancer cells are destroyed quickly. This action occurs when cells are most vulnerable. The treatment protects healthy brain tissue. It minimizes exposure to radiation. This reduces harsh side effects.
GammaTile offers distinct patient benefits. It localizes radiation (brachytherapy). This spares surrounding healthy brain cells. Patients avoid weeks of daily external radiation treatments. This alleviates travel burdens. It enhances quality of life. The collagen tiles naturally dissolve within the body. A second surgery for removal is unnecessary. This simplifies the post-operative journey. It streamlines recovery.
Clinical validation backs GammaTile’s efficacy. Final data emerged from the Phase 3 ROADS trial. This trial focused on newly diagnosed brain metastases. Results were presented at the 2026 American Society of Clinical Oncology conference. The findings were compelling. GammaTile demonstrated statistical superiority. It outperformed standard treatment. This marked a significant breakthrough.
Key metrics from the ROADS trial highlight its impact. GammaTile reduced the risk of tumor recurrence. It also lowered the risk of death at 12 months. Reductions were 93% and 41% respectively. The 12-month surgical bed recurrence rate was drastically lower. GammaTile-treated patients saw 1.3%. Standard care patients experienced 15.4%. These figures are profound. They indicate superior local control.
Median surgical bed recurrence-free survival rates were impressive. GammaTile recipients had not yet reached this milestone. Standard treatment patients reached it at 10.9 months. This suggests extended disease control. Overall survival also saw significant gains. At 24 months, GammaTile patients showed 61.7% survival. Standard care patients achieved 35.7%. These numbers represent real patient impact.
Brain tumors present complex treatment challenges. Traditional therapies often involve invasive procedures. They carry significant systemic side effects. Patients endure grueling schedules. The disease itself is aggressive. Recurrence rates are high. New approaches are desperately needed. GammaTile offers a sophisticated answer. It minimizes systemic exposure. It maximizes local control. This represents a significant step forward. It alleviates many burdens associated with conventional care. The technology offers a tailored, precise solution. It improves prognosis for patients facing dire conditions. This innovation reshapes the landscape of neurosurgical oncology. It offers a new beacon of hope.
This substantial financing empowers GT Medical Technologies. It allows them to accelerate their growth trajectory. The company focuses on improving patient outcomes. Their technology addresses critical unmet needs. Brain tumors remain a devastating diagnosis. Innovative solutions are vital. GammaTile provides such a solution.
The BRIDGES trial is the next frontier. It focuses on newly diagnosed glioblastomas. Glioblastoma is an aggressive form of brain cancer. This trial expands GammaTile’s potential application. It seeks to bring improved treatment to more patients. The goal is better survival and quality of life.
GT Medical Technologies aims to establish GammaTile as a new standard of care. This investment moves them closer. The company’s foundation rests on specialist expertise. Their focus is patient-centric innovation. They are transforming neuro-oncology. This brings hope to many.
The medical device industry watches closely. This funding round signals a major endorsement. It highlights the value of targeted, localized therapies. It underscores the importance of clinical evidence. GT Medical Technologies is poised for significant market penetration. Their technology offers clear advantages. It addresses the challenges of brain tumor management effectively.
This advancement benefits more than just the company. It impacts the entire healthcare ecosystem. Surgeons gain a powerful new tool. Oncologists have a superior option. Most importantly, patients receive enhanced care. They gain precious time. They experience reduced side effects. The future of brain tumor treatment looks brighter. GT Medical Technologies leads this charge. Their impact will be felt globally.
GT Medical Technologies received $100 million. It was an oversubscribed Series E funding round. This significant capital infusion will propel the company forward. Viking Global Investors led the financing. Existing investors also participated. These included MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, and FemHealth Ventures. The investment underscores strong confidence in GT Medical Technologies' vision. It validates their innovative approach to neuro-oncology.
The proceeds will accelerate key initiatives. Commercial expansion stands as a priority. Operational capabilities will see substantial upgrades. The company plans continued investment in clinical trials. The BRIDGES randomized controlled trial is crucial. It focuses on newly diagnosed glioblastoma patients. This funding ensures robust support for future growth. It provides flexibility for strategic investments. The goal is to redefine brain tumor treatment.
At the heart of GT Medical Technologies’ mission is GammaTile. This medical device represents a paradigm shift. It is an FDA-cleared bioresorbable radiotherapy implant. GammaTile targets operable brain tumors. Its design is ingenious. It consists of small collagen tiles. Radioactive seeds (Cesium-131) are embedded within. Surgeons implant GammaTile directly during tumor removal surgery. This happens at the time of resection. The innovative approach delivers immediate treatment.
Traditional radiation therapy often involves delays. Patients typically wait weeks after surgery. GammaTile eliminates this waiting period. It provides targeted radiation immediately. The tiles deliver a precise, focused dose. This targets the highest-risk area. Remaining cancer cells are destroyed quickly. This action occurs when cells are most vulnerable. The treatment protects healthy brain tissue. It minimizes exposure to radiation. This reduces harsh side effects.
GammaTile offers distinct patient benefits. It localizes radiation (brachytherapy). This spares surrounding healthy brain cells. Patients avoid weeks of daily external radiation treatments. This alleviates travel burdens. It enhances quality of life. The collagen tiles naturally dissolve within the body. A second surgery for removal is unnecessary. This simplifies the post-operative journey. It streamlines recovery.
Clinical validation backs GammaTile’s efficacy. Final data emerged from the Phase 3 ROADS trial. This trial focused on newly diagnosed brain metastases. Results were presented at the 2026 American Society of Clinical Oncology conference. The findings were compelling. GammaTile demonstrated statistical superiority. It outperformed standard treatment. This marked a significant breakthrough.
Key metrics from the ROADS trial highlight its impact. GammaTile reduced the risk of tumor recurrence. It also lowered the risk of death at 12 months. Reductions were 93% and 41% respectively. The 12-month surgical bed recurrence rate was drastically lower. GammaTile-treated patients saw 1.3%. Standard care patients experienced 15.4%. These figures are profound. They indicate superior local control.
Median surgical bed recurrence-free survival rates were impressive. GammaTile recipients had not yet reached this milestone. Standard treatment patients reached it at 10.9 months. This suggests extended disease control. Overall survival also saw significant gains. At 24 months, GammaTile patients showed 61.7% survival. Standard care patients achieved 35.7%. These numbers represent real patient impact.
Brain tumors present complex treatment challenges. Traditional therapies often involve invasive procedures. They carry significant systemic side effects. Patients endure grueling schedules. The disease itself is aggressive. Recurrence rates are high. New approaches are desperately needed. GammaTile offers a sophisticated answer. It minimizes systemic exposure. It maximizes local control. This represents a significant step forward. It alleviates many burdens associated with conventional care. The technology offers a tailored, precise solution. It improves prognosis for patients facing dire conditions. This innovation reshapes the landscape of neurosurgical oncology. It offers a new beacon of hope.
This substantial financing empowers GT Medical Technologies. It allows them to accelerate their growth trajectory. The company focuses on improving patient outcomes. Their technology addresses critical unmet needs. Brain tumors remain a devastating diagnosis. Innovative solutions are vital. GammaTile provides such a solution.
The BRIDGES trial is the next frontier. It focuses on newly diagnosed glioblastomas. Glioblastoma is an aggressive form of brain cancer. This trial expands GammaTile’s potential application. It seeks to bring improved treatment to more patients. The goal is better survival and quality of life.
GT Medical Technologies aims to establish GammaTile as a new standard of care. This investment moves them closer. The company’s foundation rests on specialist expertise. Their focus is patient-centric innovation. They are transforming neuro-oncology. This brings hope to many.
The medical device industry watches closely. This funding round signals a major endorsement. It highlights the value of targeted, localized therapies. It underscores the importance of clinical evidence. GT Medical Technologies is poised for significant market penetration. Their technology offers clear advantages. It addresses the challenges of brain tumor management effectively.
This advancement benefits more than just the company. It impacts the entire healthcare ecosystem. Surgeons gain a powerful new tool. Oncologists have a superior option. Most importantly, patients receive enhanced care. They gain precious time. They experience reduced side effects. The future of brain tumor treatment looks brighter. GT Medical Technologies leads this charge. Their impact will be felt globally.